ArticleBMC complementary medicine and therapies2025
Prediction of the effect of Bupleurum chinensis DC. (Chaihu) on survival and its potential targets in hepatocellular carcinoma based on a prognostic model.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is a highly invasive disease, and advanced tumours are often accompanied by a poor prognosis; thus, the treatment of advanced HCC is still based on comprehensive treatment. Bupleurum chinensis DC. (Chaihu) is widely used in the treatment of liver cancer in traditional Chinese medicine. However, few studies have explored the mechanism of action of Chaihu in hepatocellular carcinoma or its impact on prognosis.
methodsThe core target was obtained by matching differentially expressed genes (DEGs) in HCC tissues to targets associated with Chaihu. These targets were used to identify HCC subtypes and build prognostic models for patients with HCC. We also explored the immune microenvironment and enrichment pathways between different clusters. The LASSO(The Least Absolute Shrinkage and Selection Operator) regression model was used to establish a risk-score model composed of four hub genes. The Kaplan-Meier curve showed significant differences in survival between the high- and low-risk groups. The risk-score model was then combined with clinical information to develop a nomogram to predict patient survival. Finally, three hub genes identified in the prognostic model were verified using in vitro experiments.
resultsWe screened 77 prognostically relevant DEGs and selected four genes for the risk score model. Multivariate regression analysis revealed that the risk score model was an independent prognostic factor. The survival rate was significantly lower for the high-risk group than for the low-risk group (P < 0.05). In vitro experiments showed that the compounds present in Chaihu decreased the expression of prognostic genes. The combination of prognostic analysis and cell experiments showed that Chaihu exerted a potential therapeutic effect on hepatocellular carcinoma.
conclusionsThis study established a risk-scoring model for Chaihu-related genes and evaluated its effectiveness at determining the characteristics of Chaihu that are favourable for the prognosis of liver cancer. Chaihu improved the prognosis by acting on three core prognostic genes (MMP1, NQO1, and PLK1) and the immune microenvironment, thus benefiting patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.